Preclinical activity of NVL-655 in patient-derived models of ALK cancers, including those with lorlatinib-resistant G1202R/L1196M compound mutation

T. Fujino; L. Nguyen; S. Yoda; M. Yu; H. Mizuta; L. Bigot; C. Nobre; A. Tangpeerachaikul; H. E. Pelish; L. Friboulet; J. Lee; B. Cho; A. N. Hata

doi:10.1016/S0959-8049(22)01008-5

Preclinical activity of NVL-655 in patient-derived models of ALK cancers, including those with lorlatinib-resistant G1202R/L1196M compound mutation

T. Fujino, L. Nguyen, S. Yoda, M. Yu, H. Mizuta, L. Bigot, C. Nobre, A. Tangpeerachaikul, H. E. Pelish, L. Friboulet, J. Lee, B. Cho, A. N. Hata

Résultats de recherche: Contribution à un journal › Article › Revue par des pairs

1 Citation (Scopus)

langue originale	Anglais
Pages (de - à)	S78-S79
journal	European Journal of Cancer
Volume	174
Les DOIs	https://doi.org/10.1016/S0959-8049(22)01008-5
état	Publié - 1 oct. 2022

Accès au document

10.1016/S0959-8049(22)01008-5

Autres fichiers et liens

Lien vers la publication dans Scopus

Contient cette citation

Fujino, T., Nguyen, L., Yoda, S., Yu, M., Mizuta, H., Bigot, L., Nobre, C., Tangpeerachaikul, A., Pelish, H. E., Friboulet, L., Lee, J., Cho, B., & Hata, A. N. (2022). Preclinical activity of NVL-655 in patient-derived models of ALK cancers, including those with lorlatinib-resistant G1202R/L1196M compound mutation. European Journal of Cancer, 174, S78-S79. https://doi.org/10.1016/S0959-8049(22)01008-5

@article{f66b30ecf607419c8c0b8ca539f55c78,

title = "Preclinical activity of NVL-655 in patient-derived models of ALK cancers, including those with lorlatinib-resistant G1202R/L1196M compound mutation",

author = "T. Fujino and L. Nguyen and S. Yoda and M. Yu and H. Mizuta and L. Bigot and C. Nobre and A. Tangpeerachaikul and Pelish, {H. E.} and L. Friboulet and J. Lee and B. Cho and Hata, {A. N.}",

note = "Funding Information: Corporate-sponsored Research: TF, LN, SY, MY, HM, LB, CN, LF, JL, BC, and ANH receive sponsored research funding from Nuvalent. ",

year = "2022",

month = oct,

day = "1",

doi = "10.1016/S0959-8049(22)01008-5",

language = "English",

volume = "174",

pages = "S78--S79",

journal = "European Journal of Cancer",

issn = "0959-8049",

}

Fujino, T, Nguyen, L, Yoda, S, Yu, M, Mizuta, H, Bigot, L, Nobre, C, Tangpeerachaikul, A, Pelish, HE, Friboulet, L, Lee, J, Cho, B & Hata, AN 2022, 'Preclinical activity of NVL-655 in patient-derived models of ALK cancers, including those with lorlatinib-resistant G1202R/L1196M compound mutation', European Journal of Cancer, VOL. 174, p. S78-S79. https://doi.org/10.1016/S0959-8049(22)01008-5

TY - JOUR

T1 - Preclinical activity of NVL-655 in patient-derived models of ALK cancers, including those with lorlatinib-resistant G1202R/L1196M compound mutation

AU - Fujino, T.

AU - Nguyen, L.

AU - Yoda, S.

AU - Yu, M.

AU - Mizuta, H.

AU - Bigot, L.

AU - Nobre, C.

AU - Tangpeerachaikul, A.

AU - Pelish, H. E.

AU - Friboulet, L.

AU - Lee, J.

AU - Cho, B.

AU - Hata, A. N.

N1 - Funding Information: Corporate-sponsored Research: TF, LN, SY, MY, HM, LB, CN, LF, JL, BC, and ANH receive sponsored research funding from Nuvalent.

PY - 2022/10/1

Y1 - 2022/10/1

UR - http://www.scopus.com/inward/record.url?scp=85140484042&partnerID=8YFLogxK

U2 - 10.1016/S0959-8049(22)01008-5

DO - 10.1016/S0959-8049(22)01008-5

M3 - Article

AN - SCOPUS:85140484042

SN - 0959-8049

VL - 174

SP - S78-S79

JO - European Journal of Cancer

JF - European Journal of Cancer

ER -